FIELD: biochemistry.
SUBSTANCE: invention refers to antibodies that link with CTGF. Antibodies, in particular, are directed to the areas of CTFG participating in different types of biological activity related to fibrosis. The invention also refers to the method of antibodies application in pharmaceutical compositions for the treatment of CTGF-related diseases including localised and systemic fibrotic diseases such as diseases of lungs, liver, heart, skin and kidneys, for neutralisation of biological activity of CTGF and method of treatment and prophylaxis of CTGF-related diseases. The invention covers polynucleotide sequence and its variants coding the specified antibody as well as the host cell and cell line № PTA-6006 (ATCC) producing the specified antibody.
EFFECT: use of the invention provides new specific means - antibodies which effectively neutralise certain types of CTGF activity in pathology and provide specificity and pharmacokinetic profile suitable for a therapeutic agent.
82 cl, 33 dwg, 4 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALPHA-V BETA-8-BINDING ANTIBODIES | 2012 |
|
RU2614252C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) | 2015 |
|
RU2693084C2 |
| ANTI-CCR2 ANTIBODIES | 2009 |
|
RU2547595C2 |
| STRUCTURED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | 2014 |
|
RU2681502C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| ANTIBODIES AGAINST EOTAXIN 2, WHICH RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES | 2015 |
|
RU2705255C2 |
| HUMAN ANTIBODIES AGAINST SEMAPHORIN 4D | 2018 |
|
RU2776443C2 |
| DIAGNOSTIC ASSAYS AND KITS FOR DETECTION OF FOLATE RECEPTOR 1 | 2013 |
|
RU2668824C2 |
| GDF8 HUMAN ANTIBODIES | 2011 |
|
RU2710156C2 |
